Science Policy Watchers Hail New President's Early Moves

Clinton's choice of Gibbons as science adviser and Gore's anticipated activist role bode well for consideration of research issues, they contend Leading researchers as well as science policy specialists and association officials are hopeful, of course, that President Bill Clinton's administration will pursue an energetic, activist approach in tackling major science and technology issues. And, these observers generally agree, the Clinton years in this regard are off to a good start. In inter

Written byBarton Reppert
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

In interviews with The Scientist, several science and technology policy-watchers have, for example, praised Clinton's early `appointment of John H. Gibbons to be White House science and technology adviser, as well as director of the Office of Science and Technology Policy (OSTP). Gibbons, who since 1979 has been director of the congressional Office of Technology Assessment, is known around Washington as a soft-spoken but effective and politically savvy "facilitator," well accustomed to navigating Washington's turbulent policy cross-currents (see accompanying story).

"We're very enthusiastic about [Gibbons], because he knows Congress, he knows Washington, he knows the issues," says John Holmfeld, executive director of the Council of Scientific Society Presidents (CSSP), an umbrella group of the top officials from 58 scientific societies with a combined membership of 1.5 million. "Also, he can work well with [Vice President Al] Gore. All of those things add up to a big plus."

At the same ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies